繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

SHAREHOLDER ALERT: WeissLaw LLP Investigates Kadmon Holdings, Inc.

2021-09-11 05:42

NEW YORK, Sept. 10, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Kadmon Holdings, Inc. ("Kadmon Holdings" or the "Company") (NASDAQ: KDMN) in connection with the proposed acquisition of the Company by Sanofi ("Sanofi") (NASDAQ: SNY). Under the terms of the merger agreement, the Company's shareholders will receive $9.50 per share in cash for each share of Kadmon Holdings common stock that they hold. The transaction is valued at approximately $1.9 billion.

If you own Kadmon Holdings shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:

https://www.weisslaw.co/news-and-cases/kadmon-holdings-inc
Or please contact:
Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY 10036
(212) 682-3025
(888) 593-4771
[email protected]

WeissLaw LLP is investigating whether (i) Kadmon Holdings' board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $9.50 per-share merger consideration adequately compensates Kadmon Holdings' shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed. Notably, the merger consideration is below the $10.75 median of price targets set by analysts following the Company and at least one analyst set a price target for the Company of $20.00 per share, $10.50 above the per-share merger consideration.

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [email protected]

SOURCE WeissLaw LLP

Related Links

http://weisslawllp.com

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。